Medical Aspects of Biological WarfareGovernment Printing Office |
Isi
xxiii | |
21 | |
39 | |
ANTHRAX | 69 |
PLAGUE | 91 |
GLANDERS | 121 |
MELIOIDOSIS | 147 |
TULAREMIA | 167 |
RICIN | 323 |
BOTULINUM TOXIN | 337 |
ADDITIONAL TOXINS OF CLINICAL CONCERN | 355 |
LABORATORY IDENTIFICATION OF BIOLOGICAL THREATS | 391 |
CONSEQUENCE MANAGEMENT THE NATIONAL AND LOCAL RESPONSE | 415 |
MEDICAL MANAGEMENT OF POTENTIAL BIOLOGICAL CASUALTIES A STEPWISE APPROACH | 443 |
MEDICAL COUNTERMEASURES | 465 |
Chapter 22 BIOSAFETY | 515 |
BRUCELLOSIS | 185 |
Q FEVER | 199 |
SMALLPOX AND RELATED ORTHOPOXVIRUSES | 215 |
ALPHAVIRUS ENCEPHALITIDES | 241 |
VIRAL HEMORRHAGIC FEVERS | 271 |
STAPHYLOCOCCAL ENTEROTOXIN B AND RELATED TOXINS | 311 |
Istilah dan frasa umum
1425 Porter Street aerosol animal anthrax antibiotic antibody antigen Army Medical Research assay Bacillus anthracis bacterial biological agents biological warfare biological weapons biosafety bioterrorism botulinum toxin botulism Brucella Burkholderia Burkholderia pseudomallei burnetii cause cells Centers for Disease chemical ciprofloxacin Clin Microbiol clinical contaminated Control and Prevention Coxiella burnetii detection Detrick developed diagnosis Disease Control dose doxycycline Emerg Infect epidemic epidemiological exposure F tularensis Fort Detrick Francisella tularensis gene glanders hemorrhagic fever human identified Infect Immun Infectious Diseases inhalational Institute of Infectious isolated laboratory lethal mallei Maryland Medical Research Institute melioidosis mice military monkeys mycotoxins occurred organism outbreak pathogens patients personnel pestis plague postexposure potential prophylaxis protection protein pseudomallei public health Q fever reported respiratory response ribavirin ricin risk safety serotype smallpox specific strains studies symptoms syndrome T-2 toxin testing therapy threat tion titers toxic treatment trichothecene tularemia vaccine vaccinia viral virulence viruses